Toggle light / dark theme

Not everything about glass is clear. How its atoms are arranged and behave, in particular, is startlingly opaque.

The problem is that glass is an amorphous solid, a class of materials that lies in the mysterious realm between solid and liquid. Glassy materials also include polymers, or commonly used plastics. While it might appear to be stable and static, glass’ atoms are constantly shuffling in a frustratingly futile search for equilibrium. This shifty behavior has made the physics of glass nearly impossible for researchers to pin down.

Now a multi-institutional team including Northwestern University, North Dakota State University and the National Institute of Standards and Technology (NIST) has designed an algorithm with the goal of giving polymeric glasses a little more clarity. The algorithm makes it possible for researchers to create coarse-grained models to design materials with dynamic properties and predict their continually changing behaviors. Called the “energy renormalization algorithm,” it is the first to accurately predict glass’ mechanical behavior at and could result in the fast discovery of new materials, designed with optimal properties.

Read more

By Rowan Hooper

Science fiction thrillers usually send in gun-toting heroes like Will Smith or Tom Cruise to kick invading alien butt. Arrival is completely, wonderfully different: it sends in a linguist, played by Amy Adams.

“Language,” one character says, “is the first weapon drawn in a conflict.” The big question to ask the aliens: what is their purpose on Earth?

Read more

Researchers at the University of Sydney have discovered an antidote to the deadly sting delivered by the most venomous creature on earth—the Australian box jellyfish.

The Australian box jellyfish (Chironex fleckeri) has about 60 tentacles that can grow up to three metres long. Each tentacle has millions of microscopic hooks filled with .

Each box jellyfish carries enough venom to kill more than 60 humans.

Read more

New Oculus Quest is out. VR without a PC, wireless. I have had the last two iterations of the Oculus Rift, and it is truly incredible.


Oculus Quest is our first all-in-one gaming system for virtual reality. No wires. No PC. Just a headset and controllers that transport you into another world.

Read more

Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings. Study coauthor Jane Lynch, M.D., FAAP, professor of pediatrics at UT Health San Antonio, said the drug, liraglutide, in combination with an existing medication, metformin, showed robust effect in treating children studied in the Ellipse trial.

Currently only two drugs, metformin and insulin, are approved by the U.S. Food and Drug Administration for the treatment of Type 2 diabetes in children. By comparison, more than 30 drugs are approved to treat this form of diabetes in adults.

“We’ve not been able to get drugs approved for children beyond metformin and insulin,” Dr. Lynch said. “This adult diabetes medication was very effective in our trial of youth with Type 2 diabetes and was well tolerated. We urgently need other options for medical treatment of Type 2 diabetes in our youth under age 18. If approved, this drug would be a fantastic new option to complement oral metformin therapy as an alternative to insulin for our youth and adolescents with Type 2 diabetes.”

Read more

Researchers from University of Jyväskylä and Aalto University in Finland have developed a customized DNA nanostructure that can perform a predefined task in human body-like conditions. To do so, the team built a capsule-like carrier that opens and closes according to the pH level of the surrounding solution. The nanocapsule can be loaded—or packed—with a variety of cargo, closed for delivery and opened again through a subtle pH increase.

Read more

The findings, published in the journal Nature Medicine, showcase a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome. This treatment provides an important insight into the molecular pathways involved in accelerated aging, as well as how to reduce toxic proteins via gene therapy. The researchers hope to translate this therapy to humans to potentially provide a cure for progeria as well as possibly slowing down the aging process to delay the onset of age-related diseases in everyone.

Link to paper: https://www.nature.com/articles/s41591-019-0343-4

Abstract.

Read more